Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients.

Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, Meili D; Swiss Hepatitis C Cohort Study.

J Viral Hepat. 2008 Oct;15(10):747-52. doi: 10.1111/j.1365-2893.2008.01010.x. Epub 2008 Jul 10.

PMID:
18637072
[PubMed - indexed for MEDLINE]
2.

Should active injecting drug users receive treatment for chronic hepatitis C?

Papadopoulos V, Gogou A, Mylopoulou T, Mimidis K.

Arq Gastroenterol. 2010 Jul-Sep;47(3):238-41.

PMID:
21140082
[PubMed - indexed for MEDLINE]
Free Article
3.

Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes.

Robaeys G, Van Vlierberghe H, Matheï C, Van Ranst M, Bruckers L, Buntinx F; BASL Steering Committee; Benelux Study Group.

Eur J Gastroenterol Hepatol. 2006 Feb;18(2):159-66.

PMID:
16394797
[PubMed - indexed for MEDLINE]
4.

Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C.

Manolakopoulos S, Deutsch MJ, Anagnostou O, Karatapanis S, Tiniakou E, Papatheodoridis GV, Georgiou E, Manesis E, Tzourmakliotis D, Archimandritis AJ.

Liver Int. 2010 Nov;30(10):1454-60. doi: 10.1111/j.1478-3231.2010.02341.x. Epub 2010 Sep 16.

PMID:
20846344
[PubMed - indexed for MEDLINE]
5.

Chronic hepatitis C virus infection in renal transplant: treatment and outcome.

Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.

Clin Transplant. 2006 Nov-Dec;20(6):677-83.

PMID:
17100715
[PubMed - indexed for MEDLINE]
6.

Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study.

Bruggmann P, Dampz M, Gerlach T, Kravecz L, Falcato L.

Drug Alcohol Depend. 2010 Jul 1;110(1-2):167-71. doi: 10.1016/j.drugalcdep.2010.02.016. Epub 2010 Mar 23.

PMID:
20334985
[PubMed - indexed for MEDLINE]
7.

Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.

Soriano V, Maida I, Núñez M, García-Samaniego J, Barreiro P, Martín-Carbonero L, González-Lahoz J.

Antivir Ther. 2004 Dec;9(6):987-92.

PMID:
15651757
[PubMed - indexed for MEDLINE]
8.

[Virological sustained response to former young intravenous drug abusers with chronic hepatitis C treated by pegylated interferon-α plus ribavirin].

Gazdíková K, Gazdík F, Kajaba I, Hučková D, Daniš D, Okruhlica L.

Vnitr Lek. 2012 Feb;58(2):104-9. Slovak.

PMID:
22463089
[PubMed - indexed for MEDLINE]
9.

The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.

Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Frei P, Seifert B, Bischoff Ferrari HA, von Eckardstein A, Müllhaupt B, Geier A; Swiss Hepatitis C Cohort Study Group.

Antivir Ther. 2012;17(3):541-7. doi: 10.3851/IMP2018. Epub 2011 Dec 14.

PMID:
22300961
[PubMed - indexed for MEDLINE]
10.

Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection.

Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ.

Liver Int. 2009 Aug;29(7):1051-5. doi: 10.1111/j.1478-3231.2008.01958.x.

PMID:
19580634
[PubMed - indexed for MEDLINE]
11.

Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.

Al-Traif I, Handoo FA, Al-Jumah A, Al-Nasser M.

Saudi Med J. 2004 Dec;25(12):1935-8.

PMID:
15711670
[PubMed - indexed for MEDLINE]
12.

High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.

Bate JP, Colman AJ, Frost PJ, Shaw DR, Harley HA.

J Gastroenterol Hepatol. 2010 Jul;25(7):1276-80. doi: 10.1111/j.1440-1746.2010.06295.x.

PMID:
20594255
[PubMed - indexed for MEDLINE]
13.

Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.

Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK.

Dig Dis Sci. 2011 Aug;56(8):2449-55. doi: 10.1007/s10620-011-1770-3. Epub 2011 Jun 25.

PMID:
21706207
[PubMed - indexed for MEDLINE]
14.

Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.

Arase Y, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saito S, Ikeda K, Kobayashi M, Kumada H.

Intern Med. 2009;48(5):253-8. Epub 2009 Mar 2.

PMID:
19252344
[PubMed - indexed for MEDLINE]
Free Article
15.

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.

Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, Spengler U, Zeuzem S, Pape GR, Hopf U.

Liver. 2000 Dec;20(6):427-36.

PMID:
11169056
[PubMed - indexed for MEDLINE]
16.

A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.

Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF.

Antivir Ther. 2006;11(8):985-94.

PMID:
17302368
[PubMed - indexed for MEDLINE]
17.

Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.

Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M, Marschal O, Steffen M, Manns MP, Wedemeyer H.

J Hepatol. 2006 Feb;44(2):291-301. Epub 2005 Nov 28.

PMID:
16360972
[PubMed - indexed for MEDLINE]
18.

Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial.

Han Q, Liu Z, Kang W, Li H, Zhang L, Zhang N.

Dig Dis Sci. 2008 Aug;53(8):2238-45. Epub 2007 Dec 13.

PMID:
18080763
[PubMed - indexed for MEDLINE]
19.

Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.

Layden TJ, Layden JE, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU.

J Viral Hepat. 2002 Sep;9(5):334-9.

PMID:
12225327
[PubMed - indexed for MEDLINE]
20.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk